<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Genet Genomic Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol Genet Genomic Med</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2324-9269</journal-id>
<journal-id journal-id-type="publisher-id">MGG3</journal-id>
<journal-title-group>
<journal-title>Molecular Genetics &amp; Genomic Medicine</journal-title>
</journal-title-group>
<issn pub-type="epub">2324-9269</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30829465</article-id>
<article-id pub-id-type="pmc">6503008</article-id>
<article-id pub-id-type="doi">10.1002/mgg3.629</article-id>
<article-id pub-id-type="publisher-id">MGG3629</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Original Article</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Rett syndrome (<italic>MECP2</italic>) and succinic semialdehyde dehydrogenase (<italic>ALDH5A1</italic>) deficiency in a developmentally delayed female</article-title>
<alt-title alt-title-type="left-running-head">BROWN et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="mgg3629-cr-0001">
<name>
<surname>Brown</surname>
<given-names>Madalyn</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0002">
<name>
<surname>Ashcraft</surname>
<given-names>Paula</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0003">
<name>
<surname>Arning</surname>
<given-names>Erland</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0004">
<name>
<surname>Bottiglieri</surname>
<given-names>Teodoro</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0005">
<name>
<surname>McClintock</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0003">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0006">
<name>
<surname>Giancola</surname>
<given-names>Frank</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0007">
<name>
<surname>Lieberman</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0008">
<name>
<surname>Hauser</surname>
<given-names>Natalie S.</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0009">
<name>
<surname>Miller</surname>
<given-names>Rebecca</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0010">
<name>
<surname>Roullet</surname>
<given-names>Jean‐Baptiste</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="mgg3629-cr-0011">
<name>
<surname>Pearl</surname>
<given-names>Phillip</given-names>
</name>
<xref ref-type="aff" rid="mgg3629-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="mgg3629-cr-0012">
<name>
<surname>Gibson</surname>
<given-names>K. Michael</given-names>
</name>
<address>
<email>mike.gibson@wsu.edu</email>
</address>
<xref ref-type="aff" rid="mgg3629-aff-0001">
<sup>1</sup>
</xref>
</contrib>
</contrib-group>
<aff id="mgg3629-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences</named-content>
<institution>Washington State University</institution>
<named-content content-type="city">Spokane</named-content>
<named-content content-type="country-part">Washington</named-content>
</aff>
<aff id="mgg3629-aff-0002">
<label><sup>2</sup></label>
<institution>Baylor Scott &amp; White Research Institute</institution>
<institution>Institute of Metabolic Disease</institution>
<named-content content-type="city">Dallas</named-content>
<named-content content-type="country-part">Texas</named-content>
</aff>
<aff id="mgg3629-aff-0003">
<label><sup>3</sup></label>
<institution>Pediatric Specialists of Virginia</institution>
<named-content content-type="city">Fairfax</named-content>
<named-content content-type="country-part">Virginia</named-content>
</aff>
<aff id="mgg3629-aff-0004">
<label><sup>4</sup></label>
<institution>Pediatric Care of Northern Virginia</institution>
<named-content content-type="city">Manassas</named-content>
<named-content content-type="country-part">Virginia</named-content>
</aff>
<aff id="mgg3629-aff-0005">
<label><sup>5</sup></label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Boston Children’s Hospital</institution>
<institution>Harvard School of Medicine</institution>
<named-content content-type="city">Boston</named-content>
<named-content content-type="country-part">Massachusetts</named-content>
</aff>
<aff id="mgg3629-aff-0006">
<label><sup>6</sup></label>
<institution>Fulgent Genetics</institution>
<named-content content-type="city">Temple City</named-content>
<named-content content-type="country-part">California</named-content>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
K. Michael. Gibson, Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Spokane, WA.<break></break>
Email: <email>mike.gibson@wsu.edu</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2019</year>
</pub-date>
<volume>7</volume>
<issue>5</issue>
<issue-id pub-id-type="doi">10.1002/mgg3.2019.7.issue-5</issue-id>
<elocation-id>e629</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>1</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>06</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>2</month>
<year>2019</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 John Wiley & Sons Ltd. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2019 Washington State University College of Pharmacy. <italic>Molecular Genetics &amp; Genomic Medicine</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:MGG3-7-e629.pdf" xlink:type="simple"></self-uri>
<abstract id="mgg3629-abs-0001">
<title>Abstract</title>
<sec id="mgg3629-sec-0001">
<title>Background</title>
<p>We present a patient with Rett syndrome (RTT; <italic>MECP2</italic>) and autosomal‐recessive succinic semialdehyde dehydrogenase deficiency (SSADHD; <italic>ALDH5A1</italic> (aldehyde dehydrogenase 5a1 = SSADH), in whom the current phenotype exhibits features of SSADHD (hypotonia, global developmental delay) and RTT (hand stereotypies, gait anomalies).</p>
</sec>
<sec id="mgg3629-sec-0002">
<title>Methods</title>
<p>γ‐Hydroxybutyric acid (GHB) was quantified by UPLC‐tandem mass spectrometry, while mutation analysis followed standard methodology of whole‐exome sequencing.</p>
</sec>
<sec id="mgg3629-sec-0003">
<title>Results</title>
<p>The biochemical hallmark of SSADHD, GHB was increased in the proband's dried bloodspot (DBS; 673 µM; previous SSADHD DBSs (<italic>n</italic> = 7), range 124–4851 µM); control range (<italic>n</italic> = 2,831), 0–78 µM. The proband was compound heterozygous for pathogenic <italic>ALDH5A1</italic> mutations (p.(Asn418IlefsTer39); maternal; p.(Gly409Asp); paternal) and a de novo RTT nonsense mutation in <italic>MECP2</italic> (p.Arg255*).</p>
</sec>
<sec id="mgg3629-sec-0004">
<title>Conclusion</title>
<p>The major inhibitory neurotransmitter, γ‐aminobutyric acid (GABA), is increased in SSADHD but normal in RTT, although there are likely regional changes in GABA receptor distribution. GABAergic anomalies occur in both disorders, each featuring an autism spectrum phenotype. What effect the SSADHD biochemical anomalies (elevated GABA, GHB) might play in the neurodevelopmental/epileptic phenotype of our patient is currently unknown.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="mgg3629-kwd-0001">autism spectrum disorder</kwd>
<kwd id="mgg3629-kwd-0002">GABA (γ‐aminobutyric acid)</kwd>
<kwd id="mgg3629-kwd-0003">GHB (γ‐hydroxybutyric acid)</kwd>
<kwd id="mgg3629-kwd-0004">Rett syndrome</kwd>
<kwd id="mgg3629-kwd-0005">succinic semialdehyde dehydrogenase</kwd>
<kwd id="mgg3629-kwd-0006">succinic semialdehyde dehydrogenase deficiency</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="1"></table-count>
<page-count count="5"></page-count>
<word-count count="2916"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>mgg3629</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>May 2019</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.5 mode:remove_FC converted:28.06.2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="mgg3629-cit-1001" publication-type="journal">
<string-name>
<surname>Brown</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ashcraft</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Arning</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Rett syndrome (<italic>MECP2</italic>) and succinic semialdehyde dehydrogenase (<italic>ALDH5A1</italic>) deficiency in a developmentally delayed female</article-title>. <source xml:lang="en"/>Mol Genet Genomic Med. <year>2019</year>;<volume>7</volume>:<elocation-id>e629</elocation-id>
<pub-id pub-id-type="doi">10.1002/mgg3.629</pub-id>
<pub-id pub-id-type="pmid">30829465</pub-id></mixed-citation>
</p>
</notes>
</front>
<body>
<sec id="mgg3629-sec-0005">
<label>1</label>
<title>INTRODUCTION</title>
<p>Succinic semialdehyde dehydrogenase deficiency (SSADHD; <italic>ALDH5A1</italic>; OMIM 271980; HGNC: 408) is a rare, autosomal‐recessive inherited disorder in the GABA pathway (Figure <xref ref-type="fig" rid="mgg3629-fig-0001">1</xref>; DiBacco et al., <xref ref-type="ref" rid="mgg3629-bib-0007">2018</xref>).</p>
<fig fig-type="Figure" id="mgg3629-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>GABA metabolism. Produced from glutamic acid by the action of glutamic acid decarboxylase (<italic>GAD</italic>), γ‐aminobutyric acid (GABA) is metabolized in a two‐step sequence initiated by GABA‐transaminase (<italic>ABAT</italic>; 4‐aminobutyrate aminotransferase) and completed by the action of succinic semialdehyde dehydrogenase (<italic>ALDH5A1</italic>) to generate succinic acid. In patients with deficiency of <italic>ALDH5A1</italic>, succinic semialdehyde is converted to neuroactive γ‐hydroxybutyric acid by the action of aldo‐keto reductase 7a2 (<italic>AKR7A2</italic>)</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="MGG3-7-e629-g001"></graphic>
</fig>
<p>Prevalent features include hypotonia, developmental delay (especially affecting fine motor skills and expressive language), and typical imaging features involving the globus pallidi. Neuropsychiatric manifestations (OCD, ADHD) are prominent in adolescents and adults. The biochemical hallmarks include elevation of γ‐aminobutyric acid (GABA) and γ‐hydroxybutyric acid (GHB) in physiological fluids and tissues (Novotny, Fulbright, Pearl, Gibson, &amp; Rothman, <xref ref-type="ref" rid="mgg3629-bib-0019">2003</xref>). The incidence of SSADH deficiency is projected at 1:10<sup>6</sup>, but this may be an underestimate due to undiagnosed patients (Lapalme‐Remis et al., <xref ref-type="ref" rid="mgg3629-bib-0014">2015</xref>). SSADHD is a static encephalopathy, although an adult subpopulation displays a more severe, progressive course associated with epilepsy (DiBacco et al., <xref ref-type="ref" rid="mgg3629-bib-0007">2018</xref>).</p>
<p>A neurodevelopmental disorder, Rett syndrome (RTT; OMIM 312750; <italic>MECP2</italic>; HGNC: 6990) encompasses a phenotype of moderate progression associated with severe intellectual and physical disability (Leonard, Cobb, &amp; Downs, <xref ref-type="ref" rid="mgg3629-bib-0015">2017</xref>). RTT has an X‐linked dominant pattern of inheritance and mainly affects females with an approximate 1:10,000 incidence featuring predominantly de novo mutations in the methyl‐CpG‐binding protein 2 (<italic>MECP2</italic>) gene (Carter et al., <xref ref-type="ref" rid="mgg3629-bib-0003">2010</xref>; Corchón, Carrillo‐López, &amp; Cauli, <xref ref-type="ref" rid="mgg3629-bib-0006">2018</xref>; Leonard et al., <xref ref-type="ref" rid="mgg3629-bib-0015">2017</xref>). Phenotype evolution encompasses initial loss of speech and motor skill regression following apparent normal development, with decelerating head growth, hand stereotypies, gait anomalies (ataxia, apraxia), pulmonary dysfunction, mood fluctuation, and disruptive behavior (Munde, Vlaskamp, &amp; Haar, <xref ref-type="ref" rid="mgg3629-bib-0017">2016</xref>; Wong, Leonard, Jacoby, Ellaway, &amp; Downs, <xref ref-type="ref" rid="mgg3629-bib-0023">2015</xref>). We present a patient with SSADHD and RTT, disorders typically associated with autism spectrum disorder and epilepsy (Benke &amp; Möhler, <xref ref-type="ref" rid="mgg3629-bib-0001">2018</xref>; Frye et al., <xref ref-type="ref" rid="mgg3629-bib-0009">2016</xref>).</p>
</sec>
<sec id="mgg3629-sec-0006">
<label>2</label>
<title>CASE HISTORY</title>
<p>Parents provided informed consent for this study. The proband was the product of an IVF gestation (BW, 5 lbs. 14.9 oz.; length, 49.5 cm; head circumference 32 cm), Apgars 5/8. There was no birth trauma, although she needed Continuous positive airway pressure (CPAP) briefly, and had low glucose level of 47mg/dl. She was described as vigorous initially, then sleepy at the breast with poor latch. She went home with mother at 48 hr post delivery. She rolled once or twice ~6 months of age but not again, and was not sitting at 9 months of age. At that time, communication skills were delayed. Fine motor skills revealed absence of a pincer grasp and a limited raking grasp to pick up food but then with difficulty successfully transferring to her mouth. She transferred objects from the left to right hand, her dominant one, but not vice‐versa. Her hands were clumsy with intention tremor, intermittent stereotypical finger movements, and internal thumbing, although she had some preserved hand use for playing and feeding. Communication skills encompassed three signs (eat, drink, and all done), and she was able to follow simple commands. She was described as very social, with the ability to read her parents' emotions as well as express her own emotions (e.g., bruxism when stressed). She engaged in social referencing and reciprocal social interactions.</p>
<p>Physical therapy was begun at 9–10 months of age. About that time, and over the next three months, communication declined to the point of losing consonant sounds. She could sit independently at 15 months of age, although shortly thereafter had developmental regression with loss of sounds and much of her limited gross and fine motor skills. At 29 months, she was working on standing independently with a gait trainer and had persistent difficulty with motor planning. The examination at 29 months of age showed acceptable growth with weight at the mean for age and height 15%‐tile, compared to head circumference of 46.5 cm (5%‐tile). There were no dysmorphic or cutaneous stigmata. The motor systems showed decreased axial and appendicular tone with satisfactory strength, limited hand skills, and nondetectable muscle stretch reflexes.</p>
<p>Magnetic resonance imaging of brain at 13 months revealed normal myelination, although there was T2 prolongation and increased signal intensity on the diffusion‐weighted sequence involving the globus pallidus bilaterally. There was slight prominence of the sulci raising suspicion for mild, diffuse parenchymal volume loss. Electroencephalography (EEG) was initially undertaken at 28 months and was interpreted as normal. A follow‐up EEG at 36 months revealed diffuse slowing indicative of encephalopathy with bifrontal sharp slow activity intermittently. Thus far, there have been no seizures. Feeding and occupational therapy have resulted in slow progress in chewing and tongue movements. Hippotherapy, a body suit and a gait trainer have provided assistance with decreased coordination, balance, strength, as well as independent ambulation. An eye gaze computer is enabling some degree of communication/vocalization, and she has shown the capacity to shake her head to indicate “yes”.</p>
</sec>
<sec id="mgg3629-sec-0007">
<label>3</label>
<title>LABORATORY INVESTIGATION</title>
<p>Clinical exome sequencing was initially ordered and performed by Fulgent Diagnostics (Temple City, CA), employing a proprietary method as described (fulgentdiagnostics.com GenBank accession numbers: <italic>ALDH5A1</italic>, NM_001080.3; <italic>MECP2</italic>, NM_004992.3), which confirmed the dual diagnosis at 17 months of age (Table <xref ref-type="table" rid="mgg3629-tbl-0001">1</xref>). This was ordered in relation to global developmental delay of unknown etiology. Urine organic acids were subsequently requested at 18 months and revealed an elevation of GHB, which was not quantified. GHB was subsequently quantified in patient dried bloodspot (DBS; Forni, Pearl, Gibson, Yu, &amp; Sweetman, <xref ref-type="ref" rid="mgg3629-bib-0008">2013</xref>). In that study, GHB content in SSADHD DBS was compared with 2,831 archival DBS samples (including newborns, infants and children). Control GHB was 8 ± 5 µM (mean ± <italic>SD</italic>; 99.9%‐tile, 63 µM) (range 0–78 µM), while GHB content in SSADHD DBS was 124–4851 µM (range [<italic>n</italic> = 7]; median 1,182 µM, mean 699 µM). GHB in patient DBS was 673 µM (parallel control, 17 µM), 10‐fold above the 63 µM cutoff.</p>
<table-wrap id="mgg3629-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Whole‐exome sequence analysis of proband and parents</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Family member</th>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">Variant</th>
<th align="left" colspan="1" rowspan="1" valign="top">Zygosity and inheritance</th>
<th align="left" colspan="1" rowspan="1" valign="top">Comment or Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Proband</td>
<td align="left" colspan="1" rowspan="1">
<italic>ALDH5A1</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_001080.3:g.1253del<break></break>
p.(Asn418IlefsTer39)
</td>
<td align="left" colspan="1" rowspan="1">Hz, AR</td>
<td align="left" colspan="1" rowspan="1">Protein termination</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">
<italic>ALDH5A1</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_001080.3;c.1226G&gt;A<break></break>
p.(Gly409Asp)
</td>
<td align="left" colspan="1" rowspan="1">Hz, AR</td>
<td align="left" colspan="1" rowspan="1">Hogema et al. (<xref ref-type="ref" rid="mgg3629-bib-0010">2001</xref>) (&lt;1% residual <italic>ALDH5A1</italic> activity)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">
<italic>MECP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_004992.3;c.763C&gt;T<break></break>
p.Arg255*
</td>
<td align="left" colspan="1" rowspan="1">Hz, XL</td>
<td align="left" colspan="1" rowspan="1">
Christodoulou &amp; Ho (<xref ref-type="ref" rid="mgg3629-bib-0005">2012</xref>)<break></break>
Protein termination
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mother</td>
<td align="left" colspan="1" rowspan="1">
<italic>ALDH5A1</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_001080.3:g.1253del<break></break>
p.(Asn418IlefsTer39)
</td>
<td align="left" colspan="1" rowspan="1">Hz, AR</td>
<td align="left" colspan="1" rowspan="1">Protein termination</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">
<italic>MECP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_004992.3;c.763C&gt;T<break></break>
p.Arg255*
</td>
<td align="left" colspan="1" rowspan="1">Hz, XL</td>
<td align="left" colspan="1" rowspan="1">Not detected</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Father</td>
<td align="left" colspan="1" rowspan="1">
<italic>ALDH5A1</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_001080.3;c.1226G&gt;A<break></break>
p.(Gly409Asp)
</td>
<td align="left" colspan="1" rowspan="1">Hz, AR</td>
<td align="left" colspan="1" rowspan="1">Hogema et al. (<xref ref-type="ref" rid="mgg3629-bib-0010">2001</xref>) (&lt;1% residual <italic>ALDH5A1</italic> activity)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> </td>
<td align="left" colspan="1" rowspan="1">
<italic>MECP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">
NM_004992.3;c.763C&gt;T<break></break>
p.Arg255*
</td>
<td align="left" colspan="1" rowspan="1">Hz, XL</td>
<td align="left" colspan="1" rowspan="1">Not detected</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<title>Note</title>
<fn id="mgg3629-note-0001">
<p>Hz, heterozygosity; AR, autosomal recessive; XL, X‐linked; all variants are predicted to be pathogenic. GenBank accession numbers: <italic>ALDH5A1</italic>, NM_001080.3; <italic>MECP2</italic>, NM_004992.3</p>
</fn>
</table-wrap-foot>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
</sec>
<sec id="mgg3629-sec-0008">
<label>4</label>
<title>DISCUSSION</title>
<p>During the first 3.5 years of development, the phenotype of our patient appears similar to the sum of the two disorders rather than synergistically worse. Her loss of hand function, loss of speech, regression in ambulation and hand stereotypies clearly meet diagnostic criteria for classic RTT. Hypotonia, dysphagia, kyphosis, and sleep difficulties which are noted in our patient and are frequently seen in RTT (Carter et al., <xref ref-type="ref" rid="mgg3629-bib-0003">2010</xref>; Neul et al., <xref ref-type="ref" rid="mgg3629-bib-0018">2010</xref>). Many of the unique features of RTT, e.g., breathing abnormalities, are not present, although she does exhibit bruxism, is variably challenged with apraxia, and demonstrates occasional intention tremor when using her hands. Of interest, she does not exhibit any of the characteristic social delays often present in autism spectrum disorder, RTT, or SSADHD. The patient's mother describes her as having a strong sense of social reciprocity, initiation and maintenance of social routines, and with good nonverbal communication (considering her physical limitations) such as eye contact. She can understand emotion on the faces of others and responds appropriately to changes in affect with other individuals.</p>
<p>RTT and SSADHD likely share imbalanced excitatory versus inhibitory neurotransmission (Benke &amp; Möhler, <xref ref-type="ref" rid="mgg3629-bib-0001">2018</xref>; Frye et al., <xref ref-type="ref" rid="mgg3629-bib-0009">2016</xref>), perhaps underpinning to some degree the autism spectrum and epilepsy phenotype of both disorders. Of interest, patients with SSADHD have downregulated GABA(A) and GABA(B) receptors (Pearl et al., <xref ref-type="ref" rid="mgg3629-bib-0020">2009</xref>; Reis et al., <xref ref-type="ref" rid="mgg3629-bib-0022">2012</xref>). Similarly, RTT patients demonstrate lowered expression of GABA(A) receptors (Blue, Naidu, &amp; Johnston, <xref ref-type="ref" rid="mgg3629-bib-0002">1999</xref>; Yamashita et al., <xref ref-type="ref" rid="mgg3629-bib-0024">1998</xref>), and transcranial magnetic stimulation studies suggest abnormal GABA(B) receptor function (Krajnc &amp; Zidar, <xref ref-type="ref" rid="mgg3629-bib-0013">2016</xref>). In the <italic>Mecp2</italic>‐null mouse, there is evidence for fewer synaptic GABA(A) receptors (Jin, Cui, Zhong, Jin, &amp; Jiang, <xref ref-type="ref" rid="mgg3629-bib-0011">2013</xref>) and more extrasynaptic receptors, at least in the nucleus tractus solitarius (Chen et al., 2018), with upregulated response of postsynaptic GABA(A) receptors in the barrel cortex of <italic>Mecp2</italic>‐null mice (Lo et al., 2016). There is also a reported downregulation of synaptic GABA transporters in <italic>Mecp2</italic>‐null mice (Kang et al. 2014). Biochemically, patients with SSADHD have increased GABA (Novotny et al., <xref ref-type="ref" rid="mgg3629-bib-0019">2003</xref>), while GABA levels in CSF from RTT patients are normal (Perry, Dunn, Ho, &amp; Crichton, <xref ref-type="ref" rid="mgg3629-bib-0021">1988</xref>). The effect of increased GABA on the RTT neurodevelopmental phenotype (exacerbation, attenuation) remains to be determined in our patient.</p>
</sec>
<sec id="mgg3629-sec-0009" sec-type="COI-statement">
<title>CONFLICT OF INTEREST</title>
<p>Madalyn Brown, Paula Ashcraft, Erland Arning, Teodoro Bottiglieri, William McClintock, Frank Giancola, David Lieberman, Natalie Hauser, Rebecca Miller, Jean‐Baptiste Roullet, Phillip Pearl, and K. Michael Gibson declare that they have nothing to disclose and no conflict of interest.</p>
</sec>
</body>
<back>
<ack id="mgg3629-sec-0010">
<title>ACKNOWLEDGEMENTS</title>
<p>We thank the family for their support and correspondence in this study.</p>
</ack>
<ref-list content-type="cited-references" id="mgg3629-bibl-0001">
<title>REFERENCES</title>
<ref id="mgg3629-bib-0001">
<mixed-citation id="mgg3629-cit-0001" publication-type="journal">
<string-name>
<surname>Benke</surname>, <given-names>D.</given-names>
</string-name>, &amp; <string-name>
<surname>Möhler</surname>, <given-names>H.</given-names>
</string-name> (<year>2018</year>). <article-title>Impact on GABA systems in monogenetic developmental CNS disorders: Clues to symptomatic treatment</article-title>. <source xml:lang="en"/>Neuropharmacology, <volume>136</volume>(<issue>Pt A</issue>), <fpage>46</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2017.07.030</pub-id>
<pub-id pub-id-type="pmid">28764992</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0002">
<mixed-citation id="mgg3629-cit-0002" publication-type="journal">
<string-name>
<surname>Blue</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Naidu</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Johnston</surname>, <given-names>M. V.</given-names>
</string-name> (<year>1999</year>). <article-title>Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome</article-title>. <source xml:lang="en"/>Experimental Neurology, <volume>156</volume>, <fpage>345</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.1999.7030</pub-id>
<pub-id pub-id-type="pmid">10328941</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0003">
<mixed-citation id="mgg3629-cit-0003" publication-type="journal">
<string-name>
<surname>Carter</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Downs</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Bebbington</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Williams</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Jacoby</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Kaufmann</surname>, <given-names>W. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Leonard</surname>, <given-names>H.</given-names>
</string-name> (<year>2010</year>). <article-title>Stereotypical hand movements in 144 subjects with Rett syndrome from the population‐based Australian database</article-title>. <source xml:lang="en"/>Movement Disorders, <volume>25</volume>, <fpage>282</fpage>–<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1002/mds.22851</pub-id>
<pub-id pub-id-type="pmid">19908321</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0004">
<mixed-citation id="mgg3629-cit-0004" publication-type="journal">
<string-name>
<surname>Chen</surname>, <given-names>C. Y.</given-names>
</string-name>, <string-name>
<surname>Di Lucente</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>Y. C.</given-names>
</string-name>, <string-name>
<surname>Lien</surname>, <given-names>C. C.</given-names>
</string-name>, <string-name>
<surname>Rogawski</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Maezawa</surname>, <given-names>I.</given-names>
</string-name>, &amp; <string-name>
<surname>Jin</surname>, <given-names>L. W.</given-names>
</string-name> (<year>2018</year>). <article-title>Defective GABAergic neurotransmission in the nucleus tractus solitarius in Mecp2-null mice, a model of Rett syndrome</article-title>. <source xml:lang="en"/>Neurobiology of Disease, <volume>109</volume>, <fpage>25</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">28927958</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0005">
<mixed-citation id="mgg3629-cit-0005" publication-type="book">
<string-name>
<surname>Christodoulou</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Ho</surname>, <given-names>G.</given-names>
</string-name> (<year>2012</year>). <chapter-title>MECP2‐related disorders</chapter-title> In <person-group person-group-type="editor"><name><surname>Adam</surname><given-names>M. P.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Ardinger</surname><given-names>H. H.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Pagon</surname><given-names>R. A.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Wallace</surname><given-names>S. E.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Bean</surname><given-names>L. J. H.</given-names></name></person-group>, <person-group person-group-type="editor"><name><surname>Stephens</surname><given-names>K.</given-names></name></person-group>, &amp; <person-group person-group-type="editor"><name><surname>Amemiya</surname><given-names>A.</given-names></name></person-group> (Eds.), <source xml:lang="en"/>GeneReviews® [Internet]. <publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of Washington, Seattle</publisher-name>; 1993–2018. 2001 Oct 3 [updated 2012 Jun 28].</mixed-citation>
</ref>
<ref id="mgg3629-bib-0006">
<mixed-citation id="mgg3629-cit-0006" publication-type="journal">
<string-name>
<surname>Corchón</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Carrillo‐López</surname>, <given-names>I.</given-names>
</string-name>, &amp; <string-name>
<surname>Cauli</surname>, <given-names>O.</given-names>
</string-name> (<year>2018</year>). <article-title>Quality of life related to clinical features in patients with Rett syndrome and their parents: A systematic review</article-title>. <source xml:lang="en"/>Metabolic Brain Disease, <volume>33</volume>, <fpage>1801</fpage>–<lpage>1810</lpage>. <pub-id pub-id-type="doi">10.1007/s11011-018-0316-1</pub-id>
<pub-id pub-id-type="pmid">30220073</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0007">
<mixed-citation id="mgg3629-cit-0007" publication-type="journal">
<string-name>
<surname>DiBacco</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Roullet</surname>, <given-names>J.‐B.</given-names>
</string-name>, <string-name>
<surname>Kapur</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Brown</surname>, <given-names>M. N.</given-names>
</string-name>, <string-name>
<surname>Walters</surname>, <given-names>D. C.</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>, <given-names>K. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name> (<year>2018</year>). <article-title>Age‐related phenotype and biomarker changes in SSADH deficiency</article-title>. <source xml:lang="en"/>Annals of Clinical and Translational Neurology, <volume>6</volume>, <fpage>114</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.696</pub-id>
<pub-id pub-id-type="pmid">30656189</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0008">
<mixed-citation id="mgg3629-cit-0008" publication-type="journal">
<string-name>
<surname>Forni</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>Y.</given-names>
</string-name>, &amp; <string-name>
<surname>Sweetman</surname>, <given-names>L.</given-names>
</string-name> (<year>2013</year>). <article-title>Quantitation of gamma‐hydroxybutyric acid in dried blood spots: Feasibility assessment for newborn screening of succinic semialdehyde dehydrogenase (SSADH) deficiency</article-title>. <source xml:lang="en"/>Molecular Genetics and Metabolism, <volume>109</volume>, <fpage>255</fpage>–<lpage>259</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymgme.2013.05.002</pub-id>
<pub-id pub-id-type="pmid">23742746</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0009">
<mixed-citation id="mgg3629-cit-0009" publication-type="journal">
<string-name>
<surname>Frye</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Casanova</surname>, <given-names>M. F.</given-names>
</string-name>, <string-name>
<surname>Fatemi</surname>, <given-names>S. H.</given-names>
</string-name>, <string-name>
<surname>Folsom</surname>, <given-names>T. D.</given-names>
</string-name>, <string-name>
<surname>Reutiman</surname>, <given-names>T. J.</given-names>
</string-name>, <string-name>
<surname>Brown</surname>, <given-names>G. L.</given-names>
</string-name>, … <string-name>
<surname>Adams</surname>, <given-names>J. B.</given-names>
</string-name> (<year>2016</year>). <article-title>Neuropathological mechanisms of seizures in autism spectrum disorder</article-title>. <source xml:lang="en"/>Frontiers in Neuroscience, <volume>10</volume>, <fpage>192</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00192</pub-id>
<pub-id pub-id-type="pmid">27242398</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0010">
<mixed-citation id="mgg3629-cit-0010" publication-type="journal">
<string-name>
<surname>Hogema</surname>, <given-names>B. M.</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Senephansiri</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Burlingame</surname>, <given-names>T. G.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Jakobs</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Gibson</surname>, <given-names>K. M</given-names>
</string-name>. (<year>2001</year>). <article-title>Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>29</volume>(<issue>2</issue>), <fpage>212</fpage>–<lpage>216</lpage>.<pub-id pub-id-type="pmid">11544478</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0011">
<mixed-citation id="mgg3629-cit-0011" publication-type="journal">
<string-name>
<surname>Jin</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Cui</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zhong</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Jin</surname>, <given-names>X. T.</given-names>
</string-name>, &amp; <string-name>
<surname>Jiang</surname>, <given-names>C.</given-names>
</string-name> (<year>2013</year>). <article-title>GABAergic synaptic inputs of locus coeruleus neurons in wild‐type and Mecp2‐null mice</article-title>. <source xml:lang="en"/>American Journal of Physiology. Cell Physiology, <volume>304</volume>, <fpage>C844</fpage>–<lpage>C857</lpage>.<pub-id pub-id-type="pmid">23392116</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0012">
<mixed-citation id="mgg3629-cit-0012" publication-type="journal">
<string-name>
<surname>Kang</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>S. T.</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>, <given-names>M. V.</given-names>
</string-name>, &amp; <string-name>
<surname>Kadam</surname>, <given-names>S. D.</given-names>
</string-name> (<year>2014</year>). <article-title>Temporal- and Location-Specific Alterations of the GABA Recycling System in Mecp2 KO Mouse Brains</article-title>. <source xml:lang="en"/>Journal of Central Nervous System Disease, <volume>6</volume>, <fpage>21</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">24737935</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0013">
<mixed-citation id="mgg3629-cit-0013" publication-type="journal">
<string-name>
<surname>Krajnc</surname>, <given-names>N.</given-names>
</string-name>, &amp; <string-name>
<surname>Zidar</surname>, <given-names>J.</given-names>
</string-name> (<year>2016</year>). <article-title>The role of transcranial magnetic stimulation in evaluation of motor cortex excitability in Rett syndrome</article-title>. <source xml:lang="en"/>European Journal of Paediatric Neurology, <volume>20</volume>, <fpage>597</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpn.2016.03.010</pub-id>
<pub-id pub-id-type="pmid">27131828</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0014">
<mixed-citation id="mgg3629-cit-0014" publication-type="journal">
<string-name>
<surname>Lapalme‐Remis</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>, <given-names>E. C.</given-names>
</string-name>, <string-name>
<surname>De Meulemeester</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Chakraborty</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Torres</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name> (<year>2015</year>). <article-title>Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood</article-title>. <source xml:lang="en"/>Neurology, <volume>85</volume>, <fpage>861</fpage>–<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0000000000001906</pub-id>
<pub-id pub-id-type="pmid">26268900</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0015">
<mixed-citation id="mgg3629-cit-0015" publication-type="journal">
<string-name>
<surname>Leonard</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Cobb</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Downs</surname>, <given-names>J.</given-names>
</string-name> (<year>2017</year>). <article-title>Clinical and biological progress over 50 years in Rett syndrome</article-title>. <source xml:lang="en"/>Nature Reviews. Neurology, <volume>13</volume>, <fpage>37</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2016.186</pub-id>
<pub-id pub-id-type="pmid">27934853</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0016">
<mixed-citation id="mgg3629-cit-0016" publication-type="journal">
<string-name>
<surname>Lo</surname>, <given-names>F. S.</given-names>
</string-name>, <string-name>
<surname>Blue</surname>, <given-names>M. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Erzurumlu</surname>, <given-names>R. S.</given-names>
</string-name> (<year>2016</year>). <article-title>Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptormediated responses in the barrel cortex of Mecp2-null mice</article-title>. <source xml:lang="en"/>Journal of Neurophysiology, <volume>115</volume>(<issue>3</issue>), <fpage>1298</fpage>–<lpage>1306</lpage>.<pub-id pub-id-type="pmid">26683074</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0017">
<mixed-citation id="mgg3629-cit-0017" publication-type="journal">
<string-name>
<surname>Munde</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Vlaskamp</surname>, <given-names>C.</given-names>
</string-name>, &amp; <string-name>
<surname>Ter Haar</surname>, <given-names>A.</given-names>
</string-name> (<year>2016</year>). <article-title>Social‐emotional instability in individuals with Rett syndrome: Parents' experiences with second stage behaviour</article-title>. <source xml:lang="en"/>Journal of Intellectual Disability Research, <volume>60</volume>, <fpage>43</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/jir.12233</pub-id>
<pub-id pub-id-type="pmid">26497300</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0018">
<mixed-citation id="mgg3629-cit-0018" publication-type="journal">
<string-name>
<surname>Neul</surname>, <given-names>J. L.</given-names>
</string-name>, <string-name>
<surname>Kaufmann</surname>, <given-names>W. E.</given-names>
</string-name>, <string-name>
<surname>Glaze</surname>, <given-names>D. G.</given-names>
</string-name>, <string-name>
<surname>Christodoulou</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Clarke</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Bahi‐Buisson</surname>, <given-names>N.</given-names>
</string-name>, … <string-name>
<surname>Percy</surname>, <given-names>A. K.</given-names>
</string-name> (<year>2010</year>). <article-title>Rett syndrome: Revised diagnostic criteria and nomenclature</article-title>. <source xml:lang="en"/>Annals of Neurology, <volume>68</volume>, <fpage>944</fpage>–<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1002/ana.22124</pub-id>
<pub-id pub-id-type="pmid">21154482</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0019">
<mixed-citation id="mgg3629-cit-0019" publication-type="journal">
<string-name>
<surname>Novotny</surname>, <given-names>E. J.</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Fulbright</surname>, <given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>, <given-names>K. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Rothman</surname>, <given-names>D. L.</given-names>
</string-name> (<year>2003</year>). <article-title>Magnetic resonance spectroscopy of neurotransmitters in human brain</article-title>. <source xml:lang="en"/>Annals of Neurology, <volume>54</volume>(<issue>Suppl 6</issue>), <fpage>S25</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">12891651</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0020">
<mixed-citation id="mgg3629-cit-0020" publication-type="journal">
<string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Gibson</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Quezado</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Dustin</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Trzcinski</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Theodore</surname>, <given-names>W.</given-names>
</string-name> (<year>2009</year>). <article-title>Decreased GABA‐A binding on FMZ‐PET in succinic semialdehyde dehydrogenase deficiency</article-title>. <source xml:lang="en"/>Neurology, <volume>73</volume>, <fpage>423</fpage>–<lpage>429</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b163a5</pub-id>
<pub-id pub-id-type="pmid">19667317</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0021">
<mixed-citation id="mgg3629-cit-0021" publication-type="journal">
<string-name>
<surname>Perry</surname>, <given-names>T. L.</given-names>
</string-name>, <string-name>
<surname>Dunn</surname>, <given-names>H. G.</given-names>
</string-name>, <string-name>
<surname>Ho</surname>, <given-names>H. H.</given-names>
</string-name>, &amp; <string-name>
<surname>Crichton</surname>, <given-names>J. U.</given-names>
</string-name> (<year>1988</year>). <article-title>Cerebrospinal fluid values for monoamine metabolites, gamma‐aminobutyric acid, and other amino compounds in Rett syndrome</article-title>. <source xml:lang="en"/>Journal of Pediatrics, <volume>112</volume>, <fpage>234</fpage>–<lpage>238</lpage>.<pub-id pub-id-type="pmid">2448442</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0022">
<mixed-citation id="mgg3629-cit-0022" publication-type="journal">
<string-name>
<surname>Reis</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<surname>Pearl</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Fritsch</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Jung</surname>, <given-names>N. H.</given-names>
</string-name>, <string-name>
<surname>Dustin</surname>, <given-names>I.</given-names>
</string-name>, &amp; <string-name>
<surname>Theodore</surname>, <given-names>W. H.</given-names>
</string-name> (<year>2012</year>). <article-title>GABAB‐ergic motor cortex dysfunction in SSADH deficiency</article-title>. <source xml:lang="en"/>Neurology, <volume>79</volume>, <fpage>47</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1212/WNL.0b013e31825dcf71</pub-id>
<pub-id pub-id-type="pmid">22722631</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0023">
<mixed-citation id="mgg3629-cit-0023" publication-type="journal">
<string-name>
<surname>Wong</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Leonard</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Jacoby</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Ellaway</surname>, <given-names>C.</given-names>
</string-name>, &amp; <string-name>
<surname>Downs</surname>, <given-names>J.</given-names>
</string-name> (<year>2015</year>). <article-title>The trajectories of sleep disturbances in Rett syndrome</article-title>. <source xml:lang="en"/>Journal of Sleep Research, <volume>24</volume>, <fpage>223</fpage>–<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1111/jsr.12240</pub-id>
<pub-id pub-id-type="pmid">25219940</pub-id></mixed-citation>
</ref>
<ref id="mgg3629-bib-0024">
<mixed-citation id="mgg3629-cit-0024" publication-type="journal">
<string-name>
<surname>Yamashita</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Matsuishi</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Ishibashi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kimura</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Onishi</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yonekura</surname>, <given-names>Y.</given-names>
</string-name>, &amp; <string-name>
<surname>Kato</surname>, <given-names>H.</given-names>
</string-name> (<year>1998</year>). <article-title>Decrease in benzodiazepine receptor binding in the brains of adult patients with Rett syndrome</article-title>. <source xml:lang="en"/>Journal of the Neurological Sciences, <volume>154</volume>, <fpage>146</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-510X(97)00223-2</pub-id>
<pub-id pub-id-type="pmid">9562304</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>